SlideShare a Scribd company logo
Noon Gaweish
MLT
 What   are nosocomial infections?
 ◦ Nosocomial infections are a result of
   treatment in a hospital or a healthcare
   service unit, but secondary to the patient’s
   original condition.
 ◦ Usually first appears 48 hours or more
   after hospital admission or within 30 days
   after discharge.
 Most  nosocomial infections that
  occur are those of which the
  micro-organisms are multi-drug
  resistant.
 The most recent micro-organism
  that has emerged as a multi-drug
  resistant organism is
 Acinetobacter spp.
 Aim   of study:
 ◦ To explore the infection rate of
   Acinetobacter isolates, some
   epidemiological data, as well as,
   antibiotic sensitivity Khalifa
   hospital, Ajman.
 Characteristics:
 ◦ Acinetobacter spp. are aerobic
   gram negative bacilli or
   coccobacilli.
 ◦ They are oxidase negative,
   catalase positive, strictly non-
   motile saprophytes.
   Acinetobacter has many species in which few are considered clinically
    important:
   1.Acinetobacter baumannii
    2.Acinetobacter baylyi
    3.Acinetobacter bouvetii
    4.Acinetobacter calcoaceticus
    5.Acinetobacter gerneri
    6.Acinetobacter grimontii
    7.Acinetobacter haemolyticus
    8.Acinetobacter johnsonii
    9. Acinetobacter junii
    10.Acinetobacter lwoffii
    11.Acinetobacter parvus
    12.Acinetobacter radioresistens
    13.Acinetobacter schindleri
    14.Acinetobacter tandoii
    15.Acinetobacter tjernbergiae
    16.Acinetobacter towneri
    17.Acinetobacter ursingii
   While there are many species of Acinetobacter and
    all can cause human disease, A.baumannii accounts
              for 80% of reported infections.
   Pathophysiology:
    ◦ Acinetobacter spp. are non-
      pathogenic in nature but tend to
      cause oppurtunistic infections in
      patients who are immuno-
      compromised or have stayed in the
      hospital environment for a long
      duration.
◦ Acinetobacter spp. have many
  virulence factors, some of which
  are :
  1.   Polysaccharide capsule
  2.   Fimbriae
  3.   Enzymic activities
  4.   Iron acquisition
  5.   Lipopolysaccharide (LPS)
  6.   Slime production
   Clinical diseases:
    ◦ Acinetobacter spp. cause a variety of
      diseases that are mainly involved in
      organs or organ systems.
    ◦ Its colonization or infection sites usually
      involve organ systems with a high fluid
      content.
◦ Aside from causing nosocomial
  infections, Acinetobacter spp are al
  involved in community-acquired
  infections.
◦ The severity of such infections
  depends on the site of infection and
  degree of patient’s immune
  competence related to underlying
  disease.
   Epidemiology:
    ◦ They are non-fastidious saprophytes,
      therefore they are widely distributed in
      nature.
    ◦ Acinetobacter calcoaceticus’s habitat is
      soil whereas Acinetobacter baumannii has
      no natural habitat other than man.
    ◦ In general, Acinetobacter spp. inhabit
      areas where there’s an abundant source of
      soil.
   They have been found to be isolated from:
    ◦   food (hospital food)
    ◦   Ventilator equipments
    ◦   Suctioning equipments
    ◦   Infusion pumps
    ◦   Sinks
    ◦   Stainless steel trolleys
    ◦   Pillows
    ◦   Tap water
    ◦   Bed rails
   Lab diagnosis:
    ◦ Acinetobacter spp. grow rapidly on common,
      relatively simple media, including nutrient
      agars, trypticase soya agar and MacConkey
      agar.
    ◦ They form gray to white colonies on blood
      agar
    ◦ They form clear, colourless colonies typical of
      a lactose negative enteric bacteria on
      MacConkey agar.
    ◦ They are strictly aerobic and usually grow at
      37C or even at higher temperatures with an
      incubation period of 16-20 hours.
◦ A variety of selective media have proven to
  suppress the growth of other organisms to allow
  the growth of Acinetobacter spp.
◦ Herellea agar is a selective media used for the
  isolation and differentiation of gram positive and
  Neisseria spp. from Acinetobacter spp.
◦ Leeds Acinetobacter Medium (LAM) is a
  differential medium that inhibits the growth of
  gram-positive organisms and other gram-
  negative organism to allow the specific growth of
 Acinetobacter spp.
Acinetobacter baumannii
On blood agar
◦ Biochemically, Acinetobacter spp. do not ferment
  carbohydrates nor convert nitrates to nitrites.
◦ They are oxidase negative.
◦ Acinetobacter has many species with a distinct
  DNA hybridization group where on group
  oxidizes glucose and the other is considered
  non-glucose utilizing.
◦ Acinetobacter baumannii is non-hemolytic and
  glucose utilizing.
◦ Acinetobacter Iwoffii is non-hemolytic and non-
  glucose utilizing.
◦ Actinetobacter hemolyticus has beta-hemolysis
          on blood agar.
◦ Further testing includes:
  High fingerprinting with AFLP
  PCR-RFLP
  PCR
   Multi-drug resistance:
    ◦ An organism is considered resistant when
      its growth in vitro is not inhibited by an
      antimicrobial agent that has been
      considered to eradicate the organism in
      vivo.
    ◦ Being multi-drug resistant, the organism
      would be resistant to at least three classes
      of antibiotics.
   Causes of resistance:
    ◦ Administration of sub therapeutic doses of
      antimicrobial therapy
    ◦ Drug overuse
    ◦ Abbreviated or interrupted courses of
      treatment
    ◦ Poor penetration by the antimicrobial
      agent.
◦ Acinetobacter spp. are resistant to
  broad-spectrum cephalosporins, 4-
  quinolones, and to some extent the
  carbapenems.
◦ This resistance could be due to the
  inappropriate therapy that can lead
  to Acinetobacter genes with
  resistant characteristics.
   Treatment:
    ◦ Since Acinetobacter is a multi-drug
      resistant organism, therapeutic
      options for the infections it causes
      are restricted.
    ◦ Carbapenems are recognized as the
      gold-standard treatment.
 A number of 228 samples were
  analyzed.
 Samples were collected from different
  inpatients at different hospital sites
 The age of the patients ranged from
  22 years to 95 years.
 They were hospitalized in Khalifa
  hospital, Ajman between 2005 and
  2008.
   Bacteriological cultures were obtained by
    inoculating each sample into plate of Blood
    agars (anaerobic and aerobic), MacConkey
    agars, Chocolate agars, and cystine-lactose-
    electrolyte-deficient agar (CLED).
   Plates were incubated at 37C for 24-48
    hours.
   Grown organisms were counted, and in the
    case of urine, the standard loop technique
    was used.
 TheDADE BEHRING Microscan® is
 used to identify the type of
 bacteria
 ◦ And also, used for antibiotic
   sensitivity.
 Confirmatorytests such as
 oxidase was done.
   24 Acinetobacter positive cases were
    determined from a total of 228 samples.


                            Acinetobacter
                            (10.5%)


                            Other nosocomial
                            infections (89.5%)
   These results comes in agreement with the
    results reported by Katsaragakis ét al in
    Greece which were 12.6% (52/411)
   Whereas a study in India reported by K.
    Prashanth and S. Badrinath showed results of
    41.8% (n=18).
   These results conclude that the
    environmental conditions in Khalifa hospital
    and Greece’s surgical unit are better than in
    India.
   The rate of males infected was 62.5% and the
    rate of females was 37.5%.

            70

            60

            50

            40

             30
                                      Males (62.5%)
             20                       Females (37.5%)
             10
                 0

                     Acinetobacter
                       Infections
   Other studies conducted in Greece and France
    showed a percentage of 51.9% and 68%
    respectively.
   This concludes that men are more prone to
    Acinetobacter spp infections due to their
    exposure to outdoor activities.
   Also, during summer periods, men tend to
    profuse more sweat which can be considered
    as a risk factor to Acinetobacter infections.
   The table shows that 29.2% of the patient’s
    age ranged from 61-70 years.
                Acinetobacter Postive Cases

              Age Group          No.      %

                <20               0       0

                21-30             6       25

                31-40             0       0

                41-50             2       8.3

                51-60             1       4.2

                61-70             7      29.2

                71-80             4      16.7

                >80               4      16.7
   Elderly patients who are hospitalized in the
    hospital for long duration tend to exhibit
    lower immunity.
   On the other hand, there were no cases of
    Acinetobacter infection in the neonatal ICU
    which comes in disagreement with a study
    conducted in Brazil where 11 neonates out
    of 22 had the infection.
   95.8% of the Acinetobacter spp. were
    Acinetobacter baumannii.

        100

         80

         60                        A. baumannii
                                   (95.8%)
         40
                                   A. Iwoffii
         20                        (4.2%)

          0
               Acinetobacter sp.
 Theseresults correlate with a
 study conducted in India where A.
 baumannii was the main
 organism that caused
 Acinetobacter infection.
   Infections were highest in the male wards of
    the hospital with an infection rate of 50%.

          50

          40
                                              PW+NICU (0%)
          30                                  MW (50%)
                                              Maternity (4.2%
          20                                  FW (25%)
                                              ICU (16.7%)
          10                                  Other (4.2%)

          0
               Acinetobacter so. Infections
   These results come in disagreement with
    studies conducted in France, Greece and India
    where the organism was isolated from tertiary
    care unit, surgical ICU and surgical ICU
    respectively.
   Very little care may be provided in the male
    ward of Khalifa hospital, Ajman
   Although there was 0% of Acinetobacter
    infection in the NICU which concludes that
    there is extra care in that site.
   Antibiotic sensitivity testing showed that
    Acinetobacter spp. had a 95% resistance to
    Cefazolin and Nitrofurontoin 90% resistance
    to Ampicillin 10mg.
    Acinetobacter spp. exhibited 94.1%
    susceptibility to Tobramycin and 82.6 %
    sensitivity to Imipenem.
Specimens with
             Acinetobacter sp
                  infection
Sample
              No.             %

Urine         9          37.5

Pus           4          16.7

Bed sore      4          16.7

Sputum        2           8.3

Ear swab      1           4.2

HVS           1           4.2

Tracheal      1           4.2
secretions

Peritoneal    1           4.2

Nasal         1           4.2
secretions
 The rate of isolated Acinetobacter spp.
  infection was 37.5% in urine
  specimens.
 This result could be due to the
  inappropriate health care measures
  they take in Khalifa hospital, Ajman.
   Acinetobacter spp. are organisms that
  are non-pathogenic in nature.
 They are ubiquitous, non-fastidious
  organisms therefore their outbreak
  can be uncontrollable and fatal.
   To avoid Acinetobacter nosocomial infection
    outbreaks in the hospital, certain health and
    safety measures should be considered:
    ◦   Frequent hand-washing and gloves wearing.
    ◦   Use of face masks
    ◦   Surface sanitation.
    ◦   The use of aprons.
    ◦   Careful use of antibiotics or antimicrobial agents.
    ◦   Segregation of infection patients in private rooms.
 If such infections occurred in the
  hospital, Tobramycin and Imipenem
  are the drugs of choice.
 In addition, with appropriate nursing,
  careful care for patients, and
  providing a hygienic hospital
  environment in the wards, catheter-
  related infections can be prevented.
   http://en.wikipedia.org/wiki/Acinetobacter
   World journal of surgery,Daniel Villers et al 1998
   Epidimiological investigation of nosocomial Acinetobacter infections using arbitrarily primed
    PCR and pulse firled gel electrophoresis, Prashanth K, Badrinath S 2006 & Kerr KG et al 2006
   An outbreak of Acinetobacter baumannii septicemia in neonatal intensive care unit of a
    university hospital in brazil, Denise von dolinger de Brito ét al.
   http://books.google.co.uk/books?id=rawJaC1LoqEC&pg=PA34&lpg=PA34&dq=taxonomy+of+
    acinetobacter+iwoffii&source=bl&ots=0NaMBXOnKP&sig=W5MvZj6nX_PGu7risigh_bbWraA&hl
    =en&ei=MQ_vSZSzEKO7jAfV39QX&sa=X&oi=book_result&ct=result&resnum=9#PPA48,M1
   mackie and McCartney , Practical medical microbiology, Edited by J>G Collee/A.G. Fraser
   Essentials of diagnostic microbiology , Lisa Anne Shimeld
   http://www.cdc.gov/ncidod/dhqp/ar_acinetobacter.html
   http://deploymenthealthlibrary.fhp.osd.mil/products/Acinetobacter%20(1).pdf
   http://www.pubmedcentral.nih.gov/pagerender.fcgi?artid=264065&pageindex=4#page
   http://www.jmpiasi.ro/2004/12(3-4)/5.pdf
   http://www.horizonpress.com/acineto
   Bailey and Scott's - Diagnostic microbiology twelfth edition - Betty A. Forbes, Daniel F. Sahm,
    Alice S. Weiddfeld
   http://books.google.co.uk/books?id=w40IEJtzNScC&pg=PA36&lpg=PA36&dq=Acinetobacter+serology+tests&s
    ource=bl&ots=Smz3CkOw7M&sig=almSTM8mYXwZnskbyWWHoGhM9jw&hl=en&ei=As72SdT2GJDLjAf53c3DDA&
    sa=X&oi=book_result&ct=result&resnum=4#PPA37,M1
   Mim's medical microbiology by Richard v Goering, Hazel m Dockrell, Mark Zuckerman, Derek wakelin, ivan m
    Roitt, Cedroc Mims, Peter L Chiodini $th Edition
   http://en.wikipedia.org/wiki/Nosocomial_infection
   http://books.google.co.uk/books?id=Xbr0DGpJQ00C&pg=PA149&lpg=PA149&dq=enzymic+activities+in+Acin
    etobacter&source=bl&ots=7KrrNh9Jyk&sig=rAjCA23ueOJcVh1-
    MR5CH7On2fo&hl=en&ei=2jcESouXFZTMjAeH1uDdBA&sa=X&oi=book_result&ct=result&resnum=2
   http://books.google.co.uk/books?id=Eyc4sX6yWcoC&pg=PA71&lpg=PA71&dq=Acinetobacter+epidemiology&s
    ource=bl&ots=4i1TKPwiVT&sig=oPDtq87ewbfaG19DU6crj9TBD10&hl=en&ei=2IoFSr2DIYKNjAfm4Zj1BA&sa=X&
    oi=book_result&ct=result&resnum=4#PPA74,M1
   http://www.medscape.com/viewarticle/557767_3

   http://books.google.co.uk/books?id=mydBYyWOXYcC&pg=PA117&dq=antibiotics+in+Acinetobacter
   http://books.google.co.uk/books?id=Eyc4sX6yWcoC&pg=PA8&dq=Acinetobacter+resistance+to+drugs
   http://books.google.co.uk/books?id=NIhl1lClkVQC&pg=PA141&dq=Acinetobacter+resistance+to+drugs#PPA1
    30,M1
   INTRO = http://jac.oxfordjournals.org/cgi/content/full/58/3/697
   http://resources.metapress.com/pdf-preview.axd?code=h4620k325u70472g&size=largest
   http://www.absoluteastronomy.com/topics/Acinetobacter
   http://www.thefreelibrary.com/Multidrug-resistant+Acinetobacter+extremity+infections+in+soldiers-
    a0135117617
   I would like to start off by praising his All Mighty
    Allah for providing me with the strength and faith
    during my study. I would like to give my warm
    thanks and endless appreciation to Dr. Moslih El
    Moslih for his undivided attention and guidance
    through this project. My dear thanks to Dr. Reem
    head of Microbiology lab in Khalifa hospital,
    Ajman for her patience and concern. I thank my
    three best friends Mahra, Eman and Diana for
    believing in me and supporting me all through
    this project. Last but not least, I thank my
    parents and family endlessly for making me a
    better person and showering me with faith
    through every step I take.
Questions ?
              Thank you

More Related Content

What's hot

Inducible Clindamycin Resistance Test
Inducible Clindamycin Resistance TestInducible Clindamycin Resistance Test
Inducible Clindamycin Resistance Test
Dr. Samira Fattah
 
Nocardia
NocardiaNocardia
Nocardia
9844003833
 
Clinical Microbiology Scientific Poster
Clinical Microbiology Scientific PosterClinical Microbiology Scientific Poster
Clinical Microbiology Scientific Poster
Kimberly Campbell
 
Pseudomonas aeruginosa
Pseudomonas aeruginosaPseudomonas aeruginosa
Pseudomonas aeruginosa
Suprakash Das
 
Susceptibility 2023
Susceptibility 2023Susceptibility 2023
Susceptibility 2023
Margie Morgan
 
ESBL Detection
ESBL DetectionESBL Detection
ESBL Detection
Dr. Samira Fattah
 
About Morganella species
About Morganella speciesAbout Morganella species
About Morganella species
Subhas Chandra Aryal
 
Vancomycin resistance in staphylococci
Vancomycin resistance in staphylococciVancomycin resistance in staphylococci
Vancomycin resistance in staphylococci
Dr. Kanwal Deep Singh Lyall
 
Hacek
HacekHacek
Lecture 26 Pasteurella
Lecture 26 PasteurellaLecture 26 Pasteurella
Lecture 26 Pasteurella-
 
beta lactamases
beta lactamasesbeta lactamases
beta lactamases
Malathi Murugesan
 
Vibrio campylobacter helicobacter_pseudomonas
Vibrio campylobacter helicobacter_pseudomonasVibrio campylobacter helicobacter_pseudomonas
Vibrio campylobacter helicobacter_pseudomonas
Dana Sinziana Brehar-Cioflec
 
Esbl
EsblEsbl
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MDCarbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Society for Microbiology and Infection care
 
16. enterobacteriaceae
16. enterobacteriaceae16. enterobacteriaceae
16. enterobacteriaceae
mwangi nicholas
 
Carbapenemase indian final.pptx
Carbapenemase indian final.pptxCarbapenemase indian final.pptx
Carbapenemase indian final.pptx
ankaushik1
 
Klebsiella spp
Klebsiella sppKlebsiella spp
Klebsiella spp
Dr. Samira Fattah
 
Salmonella presentation
Salmonella presentationSalmonella presentation

What's hot (20)

Inducible Clindamycin Resistance Test
Inducible Clindamycin Resistance TestInducible Clindamycin Resistance Test
Inducible Clindamycin Resistance Test
 
Nocardia
NocardiaNocardia
Nocardia
 
Clinical Microbiology Scientific Poster
Clinical Microbiology Scientific PosterClinical Microbiology Scientific Poster
Clinical Microbiology Scientific Poster
 
Pseudomonas aeruginosa
Pseudomonas aeruginosaPseudomonas aeruginosa
Pseudomonas aeruginosa
 
Susceptibility 2023
Susceptibility 2023Susceptibility 2023
Susceptibility 2023
 
ESBL Detection
ESBL DetectionESBL Detection
ESBL Detection
 
Actinomyces + nocardia
Actinomyces + nocardiaActinomyces + nocardia
Actinomyces + nocardia
 
About Morganella species
About Morganella speciesAbout Morganella species
About Morganella species
 
Vancomycin resistance in staphylococci
Vancomycin resistance in staphylococciVancomycin resistance in staphylococci
Vancomycin resistance in staphylococci
 
Hacek
HacekHacek
Hacek
 
Neisseria deepa
Neisseria deepaNeisseria deepa
Neisseria deepa
 
Lecture 26 Pasteurella
Lecture 26 PasteurellaLecture 26 Pasteurella
Lecture 26 Pasteurella
 
beta lactamases
beta lactamasesbeta lactamases
beta lactamases
 
Vibrio campylobacter helicobacter_pseudomonas
Vibrio campylobacter helicobacter_pseudomonasVibrio campylobacter helicobacter_pseudomonas
Vibrio campylobacter helicobacter_pseudomonas
 
Esbl
EsblEsbl
Esbl
 
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MDCarbapenamases. facts detection and concerns by Dr.T.V.Rao MD
Carbapenamases. facts detection and concerns by Dr.T.V.Rao MD
 
16. enterobacteriaceae
16. enterobacteriaceae16. enterobacteriaceae
16. enterobacteriaceae
 
Carbapenemase indian final.pptx
Carbapenemase indian final.pptxCarbapenemase indian final.pptx
Carbapenemase indian final.pptx
 
Klebsiella spp
Klebsiella sppKlebsiella spp
Klebsiella spp
 
Salmonella presentation
Salmonella presentationSalmonella presentation
Salmonella presentation
 

Viewers also liked

Pseudomonas y acinetobacter.
Pseudomonas y acinetobacter.Pseudomonas y acinetobacter.
Pseudomonas y acinetobacter.
Ely Falon Uran
 
Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...
Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...
Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...
Enid Cruz
 
Evaluation Of Acinetobacter Infection, Eastern States Presentation
Evaluation Of Acinetobacter Infection, Eastern States PresentationEvaluation Of Acinetobacter Infection, Eastern States Presentation
Evaluation Of Acinetobacter Infection, Eastern States Presentation
nels1937
 
Biochemical reactions
Biochemical     reactionsBiochemical     reactions
Biochemical reactions
Saumya Singh
 
Mtalib baumannii acinetobacter 2
Mtalib   baumannii acinetobacter 2Mtalib   baumannii acinetobacter 2
Mtalib baumannii acinetobacter 2kl jkl
 

Viewers also liked (7)

Acinetobacter
Acinetobacter Acinetobacter
Acinetobacter
 
Pseudomonas y acinetobacter.
Pseudomonas y acinetobacter.Pseudomonas y acinetobacter.
Pseudomonas y acinetobacter.
 
Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...
Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...
Antibiotic susceptibility of multidrug-resistant nosocomial bacteria Acinetob...
 
Evaluation Of Acinetobacter Infection, Eastern States Presentation
Evaluation Of Acinetobacter Infection, Eastern States PresentationEvaluation Of Acinetobacter Infection, Eastern States Presentation
Evaluation Of Acinetobacter Infection, Eastern States Presentation
 
Acinetobacter
AcinetobacterAcinetobacter
Acinetobacter
 
Biochemical reactions
Biochemical     reactionsBiochemical     reactions
Biochemical reactions
 
Mtalib baumannii acinetobacter 2
Mtalib   baumannii acinetobacter 2Mtalib   baumannii acinetobacter 2
Mtalib baumannii acinetobacter 2
 

Similar to Presentation

Current Antibiotic Resistance Trends of Uropathogens from Outpatients in a Ni...
Current Antibiotic Resistance Trends of Uropathogens from Outpatients in a Ni...Current Antibiotic Resistance Trends of Uropathogens from Outpatients in a Ni...
Current Antibiotic Resistance Trends of Uropathogens from Outpatients in a Ni...
Healthcare and Medical Sciences
 
Peritonitis
PeritonitisPeritonitis
Changing epidimeology by jahanzaib.pptx
Changing epidimeology by jahanzaib.pptxChanging epidimeology by jahanzaib.pptx
Changing epidimeology by jahanzaib.pptx
AbdulAleemAwan1
 
Thesis presentation shreejeet
Thesis presentation shreejeetThesis presentation shreejeet
Int j healthalliedsci_2016_5_4_210_194083
Int j healthalliedsci_2016_5_4_210_194083Int j healthalliedsci_2016_5_4_210_194083
Int j healthalliedsci_2016_5_4_210_194083
Dr Muktikesh Dash, MD, PGDFM
 
Invasive candidiasis the hidden cause of sepsis
Invasive candidiasis the hidden cause of sepsisInvasive candidiasis the hidden cause of sepsis
Invasive candidiasis the hidden cause of sepsis
Khaled Taema
 
CRBSI Bundle
CRBSI BundleCRBSI Bundle
CRBSI Bundle
Apollo Hospitals
 
Urology Presentation
Urology PresentationUrology Presentation
Urology Presentation
apollohealing
 
Strep and entero
Strep and enteroStrep and entero
Strep and enteroPrbn Shah
 
Lab Investigation Bacterial Infections.pptx
Lab Investigation Bacterial Infections.pptxLab Investigation Bacterial Infections.pptx
Lab Investigation Bacterial Infections.pptx
NirajGupta622046
 
Anti Microbial Resistance (AMR)
Anti Microbial Resistance (AMR)Anti Microbial Resistance (AMR)
Anti Microbial Resistance (AMR)Dr. Manu Chaudhary
 
uti seminar.ppt
uti seminar.pptuti seminar.ppt
uti seminar.ppt
Ananya147165
 
ESKAPES_Published_January_2015
ESKAPES_Published_January_2015ESKAPES_Published_January_2015
ESKAPES_Published_January_2015Nick Barsby
 
fungal management
fungal management fungal management
fungal management
fungalinfection
 
Multi Specialty Presentation
Multi Specialty PresentationMulti Specialty Presentation
Multi Specialty Presentation
apollohealing
 
Advanced Laboratory Techniques in Poultry Disease Diagnosis
Advanced Laboratory Techniques in Poultry Disease DiagnosisAdvanced Laboratory Techniques in Poultry Disease Diagnosis
Advanced Laboratory Techniques in Poultry Disease Diagnosis
Joseph Giambrone
 

Similar to Presentation (20)

Acae Nicu Paper Final Subm Correction
Acae Nicu Paper Final Subm CorrectionAcae Nicu Paper Final Subm Correction
Acae Nicu Paper Final Subm Correction
 
Current Antibiotic Resistance Trends of Uropathogens from Outpatients in a Ni...
Current Antibiotic Resistance Trends of Uropathogens from Outpatients in a Ni...Current Antibiotic Resistance Trends of Uropathogens from Outpatients in a Ni...
Current Antibiotic Resistance Trends of Uropathogens from Outpatients in a Ni...
 
viruses-08-00300 (1)
viruses-08-00300 (1)viruses-08-00300 (1)
viruses-08-00300 (1)
 
Peritonitis
PeritonitisPeritonitis
Peritonitis
 
Changing epidimeology by jahanzaib.pptx
Changing epidimeology by jahanzaib.pptxChanging epidimeology by jahanzaib.pptx
Changing epidimeology by jahanzaib.pptx
 
Thesis presentation shreejeet
Thesis presentation shreejeetThesis presentation shreejeet
Thesis presentation shreejeet
 
Int j healthalliedsci_2016_5_4_210_194083
Int j healthalliedsci_2016_5_4_210_194083Int j healthalliedsci_2016_5_4_210_194083
Int j healthalliedsci_2016_5_4_210_194083
 
Urinary tract infections
Urinary tract infectionsUrinary tract infections
Urinary tract infections
 
Invasive candidiasis the hidden cause of sepsis
Invasive candidiasis the hidden cause of sepsisInvasive candidiasis the hidden cause of sepsis
Invasive candidiasis the hidden cause of sepsis
 
CRBSI Bundle
CRBSI BundleCRBSI Bundle
CRBSI Bundle
 
Sdrajani
SdrajaniSdrajani
Sdrajani
 
Urology Presentation
Urology PresentationUrology Presentation
Urology Presentation
 
Strep and entero
Strep and enteroStrep and entero
Strep and entero
 
Lab Investigation Bacterial Infections.pptx
Lab Investigation Bacterial Infections.pptxLab Investigation Bacterial Infections.pptx
Lab Investigation Bacterial Infections.pptx
 
Anti Microbial Resistance (AMR)
Anti Microbial Resistance (AMR)Anti Microbial Resistance (AMR)
Anti Microbial Resistance (AMR)
 
uti seminar.ppt
uti seminar.pptuti seminar.ppt
uti seminar.ppt
 
ESKAPES_Published_January_2015
ESKAPES_Published_January_2015ESKAPES_Published_January_2015
ESKAPES_Published_January_2015
 
fungal management
fungal management fungal management
fungal management
 
Multi Specialty Presentation
Multi Specialty PresentationMulti Specialty Presentation
Multi Specialty Presentation
 
Advanced Laboratory Techniques in Poultry Disease Diagnosis
Advanced Laboratory Techniques in Poultry Disease DiagnosisAdvanced Laboratory Techniques in Poultry Disease Diagnosis
Advanced Laboratory Techniques in Poultry Disease Diagnosis
 

Presentation

  • 2.
  • 3.  What are nosocomial infections? ◦ Nosocomial infections are a result of treatment in a hospital or a healthcare service unit, but secondary to the patient’s original condition. ◦ Usually first appears 48 hours or more after hospital admission or within 30 days after discharge.
  • 4.  Most nosocomial infections that occur are those of which the micro-organisms are multi-drug resistant.  The most recent micro-organism that has emerged as a multi-drug resistant organism is Acinetobacter spp.
  • 5.  Aim of study: ◦ To explore the infection rate of Acinetobacter isolates, some epidemiological data, as well as, antibiotic sensitivity Khalifa hospital, Ajman.
  • 6.  Characteristics: ◦ Acinetobacter spp. are aerobic gram negative bacilli or coccobacilli. ◦ They are oxidase negative, catalase positive, strictly non- motile saprophytes.
  • 7.
  • 8. Acinetobacter has many species in which few are considered clinically important:  1.Acinetobacter baumannii 2.Acinetobacter baylyi 3.Acinetobacter bouvetii 4.Acinetobacter calcoaceticus 5.Acinetobacter gerneri 6.Acinetobacter grimontii 7.Acinetobacter haemolyticus 8.Acinetobacter johnsonii 9. Acinetobacter junii 10.Acinetobacter lwoffii 11.Acinetobacter parvus 12.Acinetobacter radioresistens 13.Acinetobacter schindleri 14.Acinetobacter tandoii 15.Acinetobacter tjernbergiae 16.Acinetobacter towneri 17.Acinetobacter ursingii  While there are many species of Acinetobacter and all can cause human disease, A.baumannii accounts for 80% of reported infections.
  • 9. Pathophysiology: ◦ Acinetobacter spp. are non- pathogenic in nature but tend to cause oppurtunistic infections in patients who are immuno- compromised or have stayed in the hospital environment for a long duration.
  • 10. ◦ Acinetobacter spp. have many virulence factors, some of which are :  1. Polysaccharide capsule  2. Fimbriae  3. Enzymic activities  4. Iron acquisition  5. Lipopolysaccharide (LPS)  6. Slime production
  • 11. Clinical diseases: ◦ Acinetobacter spp. cause a variety of diseases that are mainly involved in organs or organ systems. ◦ Its colonization or infection sites usually involve organ systems with a high fluid content.
  • 12.
  • 13. ◦ Aside from causing nosocomial infections, Acinetobacter spp are al involved in community-acquired infections. ◦ The severity of such infections depends on the site of infection and degree of patient’s immune competence related to underlying disease.
  • 14. Epidemiology: ◦ They are non-fastidious saprophytes, therefore they are widely distributed in nature. ◦ Acinetobacter calcoaceticus’s habitat is soil whereas Acinetobacter baumannii has no natural habitat other than man. ◦ In general, Acinetobacter spp. inhabit areas where there’s an abundant source of soil.
  • 15. They have been found to be isolated from: ◦ food (hospital food) ◦ Ventilator equipments ◦ Suctioning equipments ◦ Infusion pumps ◦ Sinks ◦ Stainless steel trolleys ◦ Pillows ◦ Tap water ◦ Bed rails
  • 16.
  • 17. Lab diagnosis: ◦ Acinetobacter spp. grow rapidly on common, relatively simple media, including nutrient agars, trypticase soya agar and MacConkey agar. ◦ They form gray to white colonies on blood agar ◦ They form clear, colourless colonies typical of a lactose negative enteric bacteria on MacConkey agar. ◦ They are strictly aerobic and usually grow at 37C or even at higher temperatures with an incubation period of 16-20 hours.
  • 18. ◦ A variety of selective media have proven to suppress the growth of other organisms to allow the growth of Acinetobacter spp. ◦ Herellea agar is a selective media used for the isolation and differentiation of gram positive and Neisseria spp. from Acinetobacter spp. ◦ Leeds Acinetobacter Medium (LAM) is a differential medium that inhibits the growth of gram-positive organisms and other gram- negative organism to allow the specific growth of Acinetobacter spp.
  • 20. ◦ Biochemically, Acinetobacter spp. do not ferment carbohydrates nor convert nitrates to nitrites. ◦ They are oxidase negative. ◦ Acinetobacter has many species with a distinct DNA hybridization group where on group oxidizes glucose and the other is considered non-glucose utilizing. ◦ Acinetobacter baumannii is non-hemolytic and glucose utilizing. ◦ Acinetobacter Iwoffii is non-hemolytic and non- glucose utilizing. ◦ Actinetobacter hemolyticus has beta-hemolysis on blood agar.
  • 21. ◦ Further testing includes:  High fingerprinting with AFLP  PCR-RFLP  PCR
  • 22. Multi-drug resistance: ◦ An organism is considered resistant when its growth in vitro is not inhibited by an antimicrobial agent that has been considered to eradicate the organism in vivo. ◦ Being multi-drug resistant, the organism would be resistant to at least three classes of antibiotics.
  • 23. Causes of resistance: ◦ Administration of sub therapeutic doses of antimicrobial therapy ◦ Drug overuse ◦ Abbreviated or interrupted courses of treatment ◦ Poor penetration by the antimicrobial agent.
  • 24. ◦ Acinetobacter spp. are resistant to broad-spectrum cephalosporins, 4- quinolones, and to some extent the carbapenems. ◦ This resistance could be due to the inappropriate therapy that can lead to Acinetobacter genes with resistant characteristics.
  • 25. Treatment: ◦ Since Acinetobacter is a multi-drug resistant organism, therapeutic options for the infections it causes are restricted. ◦ Carbapenems are recognized as the gold-standard treatment.
  • 26.  A number of 228 samples were analyzed.  Samples were collected from different inpatients at different hospital sites  The age of the patients ranged from 22 years to 95 years.  They were hospitalized in Khalifa hospital, Ajman between 2005 and 2008.
  • 27. Bacteriological cultures were obtained by inoculating each sample into plate of Blood agars (anaerobic and aerobic), MacConkey agars, Chocolate agars, and cystine-lactose- electrolyte-deficient agar (CLED).  Plates were incubated at 37C for 24-48 hours.  Grown organisms were counted, and in the case of urine, the standard loop technique was used.
  • 28.  TheDADE BEHRING Microscan® is used to identify the type of bacteria ◦ And also, used for antibiotic sensitivity.  Confirmatorytests such as oxidase was done.
  • 29. 24 Acinetobacter positive cases were determined from a total of 228 samples. Acinetobacter (10.5%) Other nosocomial infections (89.5%)
  • 30. These results comes in agreement with the results reported by Katsaragakis ét al in Greece which were 12.6% (52/411)  Whereas a study in India reported by K. Prashanth and S. Badrinath showed results of 41.8% (n=18).  These results conclude that the environmental conditions in Khalifa hospital and Greece’s surgical unit are better than in India.
  • 31. The rate of males infected was 62.5% and the rate of females was 37.5%. 70 60 50 40 30 Males (62.5%) 20 Females (37.5%) 10 0 Acinetobacter Infections
  • 32. Other studies conducted in Greece and France showed a percentage of 51.9% and 68% respectively.  This concludes that men are more prone to Acinetobacter spp infections due to their exposure to outdoor activities.  Also, during summer periods, men tend to profuse more sweat which can be considered as a risk factor to Acinetobacter infections.
  • 33. The table shows that 29.2% of the patient’s age ranged from 61-70 years. Acinetobacter Postive Cases Age Group No. % <20 0 0 21-30 6 25 31-40 0 0 41-50 2 8.3 51-60 1 4.2 61-70 7 29.2 71-80 4 16.7 >80 4 16.7
  • 34. Elderly patients who are hospitalized in the hospital for long duration tend to exhibit lower immunity.  On the other hand, there were no cases of Acinetobacter infection in the neonatal ICU which comes in disagreement with a study conducted in Brazil where 11 neonates out of 22 had the infection.
  • 35. 95.8% of the Acinetobacter spp. were Acinetobacter baumannii. 100 80 60 A. baumannii (95.8%) 40 A. Iwoffii 20 (4.2%) 0 Acinetobacter sp.
  • 36.  Theseresults correlate with a study conducted in India where A. baumannii was the main organism that caused Acinetobacter infection.
  • 37. Infections were highest in the male wards of the hospital with an infection rate of 50%. 50 40 PW+NICU (0%) 30 MW (50%) Maternity (4.2% 20 FW (25%) ICU (16.7%) 10 Other (4.2%) 0 Acinetobacter so. Infections
  • 38. These results come in disagreement with studies conducted in France, Greece and India where the organism was isolated from tertiary care unit, surgical ICU and surgical ICU respectively.  Very little care may be provided in the male ward of Khalifa hospital, Ajman  Although there was 0% of Acinetobacter infection in the NICU which concludes that there is extra care in that site.
  • 39.
  • 40. Antibiotic sensitivity testing showed that Acinetobacter spp. had a 95% resistance to Cefazolin and Nitrofurontoin 90% resistance to Ampicillin 10mg.  Acinetobacter spp. exhibited 94.1% susceptibility to Tobramycin and 82.6 % sensitivity to Imipenem.
  • 41. Specimens with Acinetobacter sp infection Sample No. % Urine 9 37.5 Pus 4 16.7 Bed sore 4 16.7 Sputum 2 8.3 Ear swab 1 4.2 HVS 1 4.2 Tracheal 1 4.2 secretions Peritoneal 1 4.2 Nasal 1 4.2 secretions
  • 42.  The rate of isolated Acinetobacter spp. infection was 37.5% in urine specimens.  This result could be due to the inappropriate health care measures they take in Khalifa hospital, Ajman.
  • 43. Acinetobacter spp. are organisms that are non-pathogenic in nature.  They are ubiquitous, non-fastidious organisms therefore their outbreak can be uncontrollable and fatal.
  • 44. To avoid Acinetobacter nosocomial infection outbreaks in the hospital, certain health and safety measures should be considered: ◦ Frequent hand-washing and gloves wearing. ◦ Use of face masks ◦ Surface sanitation. ◦ The use of aprons. ◦ Careful use of antibiotics or antimicrobial agents. ◦ Segregation of infection patients in private rooms.
  • 45.  If such infections occurred in the hospital, Tobramycin and Imipenem are the drugs of choice.  In addition, with appropriate nursing, careful care for patients, and providing a hygienic hospital environment in the wards, catheter- related infections can be prevented.
  • 46. http://en.wikipedia.org/wiki/Acinetobacter  World journal of surgery,Daniel Villers et al 1998  Epidimiological investigation of nosocomial Acinetobacter infections using arbitrarily primed PCR and pulse firled gel electrophoresis, Prashanth K, Badrinath S 2006 & Kerr KG et al 2006  An outbreak of Acinetobacter baumannii septicemia in neonatal intensive care unit of a university hospital in brazil, Denise von dolinger de Brito ét al.  http://books.google.co.uk/books?id=rawJaC1LoqEC&pg=PA34&lpg=PA34&dq=taxonomy+of+ acinetobacter+iwoffii&source=bl&ots=0NaMBXOnKP&sig=W5MvZj6nX_PGu7risigh_bbWraA&hl =en&ei=MQ_vSZSzEKO7jAfV39QX&sa=X&oi=book_result&ct=result&resnum=9#PPA48,M1  mackie and McCartney , Practical medical microbiology, Edited by J>G Collee/A.G. Fraser  Essentials of diagnostic microbiology , Lisa Anne Shimeld  http://www.cdc.gov/ncidod/dhqp/ar_acinetobacter.html  http://deploymenthealthlibrary.fhp.osd.mil/products/Acinetobacter%20(1).pdf  http://www.pubmedcentral.nih.gov/pagerender.fcgi?artid=264065&pageindex=4#page  http://www.jmpiasi.ro/2004/12(3-4)/5.pdf  http://www.horizonpress.com/acineto  Bailey and Scott's - Diagnostic microbiology twelfth edition - Betty A. Forbes, Daniel F. Sahm, Alice S. Weiddfeld
  • 47. http://books.google.co.uk/books?id=w40IEJtzNScC&pg=PA36&lpg=PA36&dq=Acinetobacter+serology+tests&s ource=bl&ots=Smz3CkOw7M&sig=almSTM8mYXwZnskbyWWHoGhM9jw&hl=en&ei=As72SdT2GJDLjAf53c3DDA& sa=X&oi=book_result&ct=result&resnum=4#PPA37,M1  Mim's medical microbiology by Richard v Goering, Hazel m Dockrell, Mark Zuckerman, Derek wakelin, ivan m Roitt, Cedroc Mims, Peter L Chiodini $th Edition  http://en.wikipedia.org/wiki/Nosocomial_infection  http://books.google.co.uk/books?id=Xbr0DGpJQ00C&pg=PA149&lpg=PA149&dq=enzymic+activities+in+Acin etobacter&source=bl&ots=7KrrNh9Jyk&sig=rAjCA23ueOJcVh1- MR5CH7On2fo&hl=en&ei=2jcESouXFZTMjAeH1uDdBA&sa=X&oi=book_result&ct=result&resnum=2  http://books.google.co.uk/books?id=Eyc4sX6yWcoC&pg=PA71&lpg=PA71&dq=Acinetobacter+epidemiology&s ource=bl&ots=4i1TKPwiVT&sig=oPDtq87ewbfaG19DU6crj9TBD10&hl=en&ei=2IoFSr2DIYKNjAfm4Zj1BA&sa=X& oi=book_result&ct=result&resnum=4#PPA74,M1  http://www.medscape.com/viewarticle/557767_3   http://books.google.co.uk/books?id=mydBYyWOXYcC&pg=PA117&dq=antibiotics+in+Acinetobacter  http://books.google.co.uk/books?id=Eyc4sX6yWcoC&pg=PA8&dq=Acinetobacter+resistance+to+drugs  http://books.google.co.uk/books?id=NIhl1lClkVQC&pg=PA141&dq=Acinetobacter+resistance+to+drugs#PPA1 30,M1  INTRO = http://jac.oxfordjournals.org/cgi/content/full/58/3/697  http://resources.metapress.com/pdf-preview.axd?code=h4620k325u70472g&size=largest  http://www.absoluteastronomy.com/topics/Acinetobacter  http://www.thefreelibrary.com/Multidrug-resistant+Acinetobacter+extremity+infections+in+soldiers- a0135117617
  • 48. I would like to start off by praising his All Mighty Allah for providing me with the strength and faith during my study. I would like to give my warm thanks and endless appreciation to Dr. Moslih El Moslih for his undivided attention and guidance through this project. My dear thanks to Dr. Reem head of Microbiology lab in Khalifa hospital, Ajman for her patience and concern. I thank my three best friends Mahra, Eman and Diana for believing in me and supporting me all through this project. Last but not least, I thank my parents and family endlessly for making me a better person and showering me with faith through every step I take.
  • 49. Questions ? Thank you